Discover Algeria | About us | Press area | Contact | ||||||||
|
Les derniers textes juridiques
View more
Les interviews By AlgeriaInvest
Newsletter
NEW OPPORTUNITIES
NEW NEWS
September 9, 2024 | 4 months ago
Sharing
This acquisition is part of Saidal's ambitious growth plan, aimed at boosting its production capacity and diversifying its drug offering in Algeria. The partnership between the two pharmaceutical giants has lasted almost 25 years, with a successful collaboration that began with the production of part of Sanofi's therapeutic portfolio in Algeria.
On June 25, 2024, both companies signed a new agreement to produce insulins, starting in the same year. This partnership will enable to provide Algerian patients with innovative therapeutic solutions, while ensuring their long-term availability and reducing healthcare costs. In addition to insulins, this agreement also includes production of the Hexavalent pediatric vaccine, monoclonal antibodies, and several latest-generation anti-cancer drugs.
Thanks to this takeover and the extension of their collaboration, Saidal and Sanofi are reasserting their commitment to strengthening local drug production and meeting the growing needs of the Algerian market.
Sharing